Briacell Therapeutics Corp. has had a mixed week as it navigates recent developments in its clinical pipeline.
Briacell Therapeutics Corp (BCT.TO) closed at C$4.97 on Monday, reflecting a slight increase of 0.58% for the day but a notable decline of 6.65% over the week. Despite this downturn, the company is making progress in its clinical programs, which could influence investor sentiment moving forward.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$51.42M
52W high
$20.40
52W low
$3.68
1W change
+17.26%
Beta
1.53
Analyst Price Targets
Based on analyst covering BCT · as of Sep 17, 2026
Wall Street analysts forecast BCT stock price to rise 238.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+238.4% Upside
Current Price
C$5.91
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
91.6%
Annualized
90-Day Vol
91.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$7.07
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$6.27 | C$4.57 – C$8.60 |
| 60 trading days | C$6.66 | C$4.26 – C$10.41 |
| 90 trading days | C$7.07 | C$4.09 – C$12.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Keep an eye on Briacell Therapeutics as it advances its immunotherapy candidates and manages its recent stock performance. Upcoming clinical developments and partnerships could significantly impact its future trajectory.
C$4.97 closing price on Monday, with a 1D increase of 0.58%.
The stock has faced a steep decline of 47.15% year-to-date, indicating potential volatility and investor caution.
Bull case
The completion of manufacturing clinical supplies for Bria-PROS+, along with positive clinical trial data, could boost Briacell's credibility and attract further investment, potentially leading to a recovery in its stock price.
Bear case
The significant year-to-date decline in stock price and the company's challenging financial metrics may raise concerns for investors, especially in the competitive landscape of cancer therapeutics.
Price Action Overview
Advertisement
Briacell Therapeutics Corp. (BCT.TO) closed at C$4.97 on Monday, marking a 0.58% increase for the day. However, the stock has experienced a significant decline of 6.65% over the past week, contributing to a year-to-date drop of 47.15%. The latest trading volume was 13,588 shares, notably higher than the 20-day average volume of 6,971 shares, indicating increased trading activity.
Recent Developments
This week, Briacell made headlines by completing the manufacturing of clinical supplies for Bria-PROS+, a next-generation personalized immunotherapy candidate for prostate cancer. The company also announced a partnership with Uneedle to develop a scalable microneedle administration system for Bria-IMT™, which could improve treatment delivery. Additionally, positive clinical data presented at the ASCO 2026 meeting and a favorable recommendation from the Data Safety Monitoring Board for its Phase 3 study in metastatic breast cancer may enhance investor confidence.
Technical Picture
From a technical perspective, Briacell's stock is currently trading above its 50-day moving average of C$4.90, indicating a slight bullish sentiment in the short term. However, it remains significantly below its 200-day moving average of C$6.89, suggesting a longer-term bearish trend. The stock has a beta of 1.52, indicating higher volatility compared to the broader market. The 52-week range for BCT.TO is C$3.68 to C$20.40, with the current price reflecting only 8% of this range.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
